Table 4A. Univariate analysis of clinicopathological variables in relation to disease-free and overall survival.
|
Disease-free survival |
Overall survival |
|||||
|---|---|---|---|---|---|---|
| Factor | P | Hazard ratio | 95% Cl | P | Hazard ratio | 95% Cl |
| Age ⩾70 years | 0.094 | 0.502 | 0.224–1.125 | 0.504 | 0.673 | 0.211–2.148 |
| Sex (male) | 0.844 | 0.921 | 0.404–2.101 | 0.258 | 0.520 | 0.167–1.616 |
| Diabetes mellitus (+) | 0.235 | 1.631 | 0.727–3.659 | 0.807 | 1.157 | 0.358–3.740 |
| Family cancer history (+) | 0.701 | 0.844 | 0.356–2.001 | 0.079 | 0.291 | 0.073–1.154 |
| NACRT (+) | 0.338 | 0.591 | 0.202–1.732 | 0.970 | 0.975 | 0.262–3.626 |
| Perioperative Adjuvant (PI) (+) | 0.805 | 1.117 | 0.464–2.688 | 0.910 | 0.926 | 0.248–3.465 |
| Operative time ⩾450 min | 0.720 | 1.159 | 0.518–2.592 | 0.185 | 2.272 | 0.675–7.644 |
| Amount of bleeding ⩾310 g | 0.608 | 1.237 | 0.548–2.792 | 0.742 | 1.230 | 0.358–4.226 |
| Complication (Clavien–Dindo ⩾IIIa) (+) | 0.717 | 0.817 | 0.272–2.437 | 0.569 | 0.640 | 0.138–2.967 |
| Lymphatic infiltration (0 or 1) | 0.127 | 0.503 | 0.208–1.215 | 0.432 | 0.613 | 0.181–2.074 |
| Venous infiltration (0 or 1) | 0.022 | 0.270 | 0.088–0.829 | 0.599 | 0.719 | 0.211–2.452 |
| Neural infiltration (0 or 1) | 0.271 | 0.621 | 0.266–1.451 | 0.353 | 0.567 | 0.172–1.875 |
| Serosal invasion (+) | 0.004 | 3.474 | 1.487–8.117 | 0.138 | 2.555 | 0.741–8.813 |
| Retropancreatic tissue invasion (+) | 0.036 | 4.730 | 1.107–20.219 | 0.467 | 1.760 | 0.384–8.072 |
| Distal bile duct invasion (+) | 0.443 | 0.709 | 0.295–1.708 | 0.313 | 0.509 | 0.137–1.890 |
| Duodenal invasion (+) | 0.981 | 0.990 | 0.451–2.175 | 0.102 | 0.364 | 0.109–1.223 |
| Extrapancreatic nerve plexus invasion (+) | 0.988 | 1.008 | 0.375–2.713 | 0.592 | 1.444 | 0.367–5.545 |
| Vascular invasion | 0.301 | 1.524 | 0.686–3.385 | 0.322 | 1.799 | 0.562–5.760 |
| Lymph node metastasis | 0.845 | 1.114 | 0.380–3.267 | 0.949 | 0.934 | 0.116–7.535 |
| Resection margin (R0) | 0.177 | 0.545 | 0.225–1.317 | 0.123 | 0.376 | 0.109–1.301 |
| KRAS mutations in preoperative serum (pre+) | 0.710 | 1.182 | 0.489–2.858 | 0.258 | 0.306 | 0.039–2.381 |
| KRAS mutations in postoperative serum (post+) | 0.052 | 2.200 | 0.993–4.873 | 0.060 | 3.184 | 0.951–10.656 |
|
Changes in preoperative and postoperative sera | ||||||
| Group 1 (pre−/post−) | 0.138 | 0.538 | 0.237–1.221 | 0.263 | 0.497 | 0.146–1.691 |
| Group 2 (pre−/post+) | 0.166 | 1.808 | 0.783–4.177 | 0.025 | 4.155 | 1.197–14.425 |
| Group 3 (pre+/post−) | 0.533 | 0.631 | 0.148–2.686 | 0.417 | 0.039 | 0.000–96.852 |
| Group 4 (pre+/post+) | 0.267 | 1.772 | 0.645–4.871 | 0.751 | 0.712 | 0.087–5.792 |
Abbreviations: CI=confidence interval; NACRT=neo-adjuvant chemoradiotherapy.